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Abstract
Vitamin D deficiency has been widely reported among pregnant women and infants around 
the world. Women with low sun exposure, high BMI, low vitamin D intakes and 
socioeconomic disadvantage with poor quality diets are at greatest risk of vitamin D 
deficiency, leading to very low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in 
their offspring and an increased risk of nutritional rickets. Many observational studies, 
supported by compelling in vitro and in vivo data, have generated evidence suggesting that 
low vitamin D status in pregnancy may also contribute to the risk of adverse perinatal 
outcomes including hypertensive disorders (e.g., preeclampsia), fetal growth restriction, and 
preterm birth. However, the few large randomized controlled trials (RCTs) conducted to date 
have generated conflicting evidence for a role of vitamin D supplementation in improving 
perinatal outcomes. Vitamin D supplementation policies during pregnancy and 
implementation of policies vary within and between jurisdictions. Regulatory authorities have 
cited insufficient evidence to establish pregnancy-specific targets for serum 25(OH)D 
concentrations or prenatal vitamin D intake that effectively reduce the risks of adverse 
perinatal and infant outcomes. This paper arises from a Debate on Vitamin D Requirements 
during Pregnancy, held at the 22nd Vitamin D Workshop, 2019. From varied perspectives, our 
objectives were to evaluate the evidence for: vitamin D metabolism in pregnancy and the 
prevalence of gestational vitamin D deficiency worldwide; the translation of laboratory 
research findings to clinical studies on the role of vitamin D in perinatal health; the 
challenges of designing and conducting clinical trials to establish prenatal vitamin D 
requirements; and results to date of major large RCTs of prenatal vitamin D supplementation. 
Lastly, we explored potential next steps towards generating robust clinical data in this field to 
address both public health protection and patient care. 
Key-words: Vitamin D; Vitamin D Requirements; Pregnancy; Perinatal health; Vitamin D 
status
1 Introduction
2 Pregnancy and infancy are life-stages for which evidence of low vitamin D status is 
3 widespread but the evidence basis for setting dietary requirements for vitamin D is weakest 
4 (Institute of Medicine, 2011). Prevention of low vitamin D status is required to reduce the 
5 risk of nutritional rickets among children and adolescents and osteomalacia in adults, which 
6 can have severe and lasting consequences for bone growth and skeletal integrity (Munns et al 
7 2016). The recent discovery of non-skeletal roles for vitamin D has changed the landscape 
8 considerably and mechanistic studies have elaborated the molecular roles of vitamin D in 
9 many systems, for example, immunity (Adams and Hewison, 2008, Chun et al., 2014b). 
10 Modulation of the intrauterine immune environment by vitamin D has been implicated in 
11 adverse perinatal outcomes, including recurrent pregnancy loss, preeclampsia and 
12 spontaneous preterm birth (Liu and Hewison, 2012, Tamblyn et al., 2015). Indications are 
13 that early pregnancy may be the critical window for prevention of these adverse events. 
14 The definition of healthy vitamin D status during pregnancy, typically indicated by 
15 circulating concentrations of 25-hydroxyvitamin D (25(OH)D), is the subject of intense 
16 debate, which has been challenged by a lack of data from well-powered, well-controlled trials 
17 in pregnant women, particularly among women with low circulating 25(OH)D at baseline. 
18 Multiple systematic reviews of the role of vitamin D supplementation during pregnancy have 
19 been published but these have lacked data from substantial trials and there is no consensus as 
20 to whether physiological requirements for 25(OH)D are higher during pregnancy than in non-
21 pregnant adults (Roth et al., 2017). It is also worth noting that trials and reviews of trials have 
22 framed the question around the benefit of additional vitamin D supplementation during 
23 pregnancy (using a pharmacological model of intervention regardless of baseline status) 
24 rather than the role of sufficient vitamin D to support healthy pregnancy from the outset.
25 A Debate on the controversial topic of Vitamin D Requirements during Pregnancy was held 
26 at the 22nd Vitamin D Workshop, 2019. Our objectives were to evaluate the current state of 
27 the evidence for: 
28  vitamin D metabolism in pregnancy, and the prevalence of gestational vitamin D 
29 deficiency worldwide; 
30  the translation of laboratory research findings to clinical studies on the role of vitamin 
31 D in perinatal health; 
32  the challenges of designing and conducting clinical trials to establish prenatal vitamin 
33 D requirements; and, 
34  results to date of major large RCTs of prenatal vitamin D supplementation. 
35 The three authors hold some shared and some divergent views on the core issues discussed 
36 and provided their perspectives on these issues. Our common goal was to explore potential 
37 next steps towards generating robust clinical data in this field to address both public health 
38 protection and patient care. In the presentation of the evidence in this paper, we aimed to 
39 convey the plurality of divergent viewpoints rather than present a unified or consensus 
40 statement.   
41 Low vitamin D status is common among pregnant women and infants
42 A key question to be addressed is whether the prevalence of 25(OH)D <25-30 and <50 
43 nmol/L is higher among pregnant women than among other population groups. Saraf and 
44 colleagues (2016) estimated the global prevalence of 25(OH)D concentrations < 50 nmol/L at 
45 54% among pregnant women and 75% among newborns. Almost one in five pregnant women 
46 and one in three newborns were below 25 nmol/L, placing them at increased risk of 
47 developing rickets and osteomalacia. A systematic review of 25(OH)D concentrations in low- 
48 and middle-income countries (LMIC) by Cashman et al (2019) reported that 29 out of the 83 
49 countries included had 25(OH)D data available. Afghanistan, Pakistan, India, Tunisia, Syria, 
50 the West Bank and Gaza and Mongolia were classified as “hot spots” for very low 25(OH)D 
51 (<25-30 nmol/L) among women, pregnant women or infants on the basis of having a 
52 prevalence in excess of 20%(Cashman et al., 2019). In low income and middle eastern 
53 countries in particular, women and girls appear to have lower circulating 25(OH)D than their 
54 male counterparts, probably due to clothing practices (Roth et al., 2018a, Lips et al., 2019). 
55 Palacios and Gonzales (2014) described a high prevalence (>20%) of 25(OH)D <30 nmol/L 
56 among pregnant women and infants, in many countries, including in South Asia and the 
57 Middle East; up to 60% of women in India and 86% of infants in Iran had 25(OH)D < 30 
58 nmol/L. 
59 One of the challenges of interpreting global 25(OH)D data is the methodological variability 
60 in analytical methods and data reporting, which can be particularly challenging for maternal 
61 samples (Best et al 2019). The relatively low uptake, and low rate reporting of laboratory 
62 performance of users of quality assurance systems, such as DEQAS (Carter et al 2017), leads 
63 to a lack of transparency. Application of the NIH Vitamin D Standardization Protocol 
64 (VDSP) should be used to standardize 25(OH)D data if serum aliquots are available for re-
65 analysis by LC-MS/MS, using a validated statistical approach (Durazo-Arvizu et al 2017). 
66 The CDC Vitamin D Standardization-Certification Program (VDSCP) is also available as an 
67 avenue to achieve accreditation of 25(OH)D analysis. 
68 Within temperate countries, the prevalence of vitamin D deficiency is much higher among 
69 persons with darkly pigmented skin tones. Using VDSP, the ODIN project reported the first 
70 internationally standardised dataset of vitamin D status and the prevalence of vitamin D 
71 deficiency across Europe (Cashman et al., 2016). While the overall prevalence of 25(OH)D < 
72 30 nmol/L was 13%, about twice that of the US (5.9%) (Schleicher et al., 2016) and Canada 
73 (7.4%) (Sarafin et al., 2015), persons with more darkly pigmented skin tones were at much 
74 higher risk than their white counterparts both in Europe and North America. As part of the 
75 ODIN project, Kiely et al. (2016) analysed a pregnancy cohort of 1800 women in Ireland, 
76 where there is no maternal vitamin D supplementation policy. Data from CDC-accredited 
77 LC/MS-MS analysis of 25(OH)D showed that 17% were below 30 nmol/L at 15 weeks of 
78 gestation; this was 49% among women of ethnic minority (Kiely et al., 2016). Among the 
79 infants of this cohort, 46% of umbilical cord sera had a 25(OH)D < 30 nmol/L; this was 73% 
80 among infants from women of ethnic minority (Kiely et al., 2017b). 
81 Nutritional Rickets
82 In line with the prevalence data for 25(OH)D among mothers and newborns, it is no surprise 
83 to note that the greatest burden of nutritional rickets is in Africa, Asia and the Middle East 
84 (Thacher et al., 2006, Prentice, 2013). There is also evidence that while the incidence of 
85 nutritional rickets is stable or decreasing among whites, it is increasing in North America and 
86 Europe among immigrant populations (Creo et al., 2017). Thacher et al (2016) provided a 
87 summary of nutritional rickets in immigrant and refugee children using data collected in the 
88 UK, Denmark, Australia, Canada and the US. Populations most at risk were South Asian, 
89 African and Middle Eastern African, with incidence rates (per 1000,000/year) up to 24 in 
90 young children < 3 years and up to 4.9 among children <15 years. The stark contrast between 
91 whites and ethnic minorities in western countries is highlighted in the Global Consensus 
92 Recommendations on Prevention and Management of Nutritional Rickets (Munns et al., 
93 2016). Most clinical insights are gained from hospital admissions; Uday et al (2018) have 
94 documented hypocalcemic dilated cardiomyopathy associated with nutritional rickets and in 
95 some cases, fatal consequences. These prevalence estimates of maternal and infant 25(OH)D 
96 concentrations and the resulting effects elevate vitamin D deficiency among mothers and 
97 babies to the status of a serious public health problem that requires urgent action. 
98
99 Challenges in defining nutritional requirements for vitamin D during pregnancy
100 To provide the policy context, Mairead Kiely (MK) also summarized current dietary 
101 recommendations for vitamin D in in pregnant and lactating women in line with the 25(OH)D 
102 concentration targets they are intended to reach. Individual intake recommendations range 
103 from 5 to 15 µg/day (200-600 IU) to achieve 25(OH)D targets of > 25 to 50 nmol/L (10 to 20 
104 ng/mL) (Kiely et al., 2017a). Although there is some variation between these 
105 recommendations, they were all formulated based on evidence from RCTs of vitamin D 
106 status and bone health outcomes. Due to a lack of evidence on which to set nutritional 
107 requirements for 25(OH)D during pregnancy specifically,  recommendations for vitamin D 
108 intake are the same for pregnant and lactating women as non-pregnant adults.
109 Vitamin D requirements from the perspective of vitamin D biology
110 Carol Wagner (CW) presented data showing that unlike other times during the lifespan, 
111 pregnancy involves the orchestration of events that must protect the mother while allowing 
112 growth and development of the fetus. There is a delicate immune balance that nurtures the 
113 allogeneic fetus, while maintaining reactivity against pathogens to the outside world (Racicot 
114 et al., 2014, Mor and Cardenas, 2010, Vijayendra Chary et al., 2015a). During the first 
115 trimester, a proinflammatory state allows for the invasion of the uterine wall by fetal derived 
116 cytotrophoblast cells to become the placenta. Following the establishment of the maternal-
117 placental-embryonic unit, there is rapid growth of the fetus, which must occur in a state that 
118 is by comparison to the earlier first stage of pregnancy, anti-inflammatory (Racicot et al., 
119 2014, Mor and Cardenas, 2010). This relatively anti-inflammatory state will last well beyond 
120 the second trimester and into the third trimester, when the uterine environment becomes more 
121 proinflammatory to allow the onset of labour and the expulsion of the fetus from the uterus 
122 (Racicot et al., 2014, Mor and Cardenas, 2010). Dysregulation of these tightly controlled 
123 biophenomena at a systemic and placental level have been considered as a 
124 potential mechanism mediating pathogenesis of recurrent pregnancy loss (Ji et al., 2019) 
125 preeclampsia and spontaneous preterm birth (Weiss et al., 2016, Mirzakhani et al., 2016). It is 
126 postulated by many that these adverse events during pregnancy have their origins early-on in 
127 pregnancy, with derangement of the critical balance in immune function (Hollis and Wagner, 
128 2017b, Liu and Hewison, 2012, Tamblyn et al., 2015).
129 1,25(OH)2D mediates gene expression via VDR and VDREs, and increased concentrations of 
130 1,25(OH)2D could have implication for gene pathways and subsequent function. In mouse 
131 models of vitamin D deficiency studied early in gestation, an array of genes in the placenta are 
132 upregulated and others downregulated based on maternal vitamin D status (Liu et al., 2011), 
133 which find corollaries in human studies, especially following adverse pregnancy outcomes 
134 such as preeclampsia (Powe et al., 2010, Robinson et al., 2010, Baker et al., 2010, Bodnar et 
135 al., 2014, Mirzakhani et al., 2016). Parallel findings are noted in the upregulation of certain 
136 placental genes that have been implicated in preeclampsia (Schulz et al., 2017). There are 
137 studies that describe alternation in T cell phenotype associated with preterm birth (Zahran et 
138 al., 2018) and recurrent pregnancy loss in women who are vitamin D deficient (Ji et al., 2019, 
139 Kwak-Kim et al., 2016, Wu et al., 2018, Sharif et al., 2018). There are also non-genomic 
140 calcitriol-dependent biological effects that can take place in cells, involving second messengers 
141 generated by membrane-initiated signalling pathways (Novakovic et al., 2009). 
142 Classic vitamin D receptor (VDR) and the membrane-associated rapid response steroid-
143 binding protein (MARRS) found in the cell membrane may bind 1,25(OH)2D and initiate the 
144 activation of numerous pathways involving various protein kinases (PKC), MAPK, PKA, 
145 phosphatidyl inositol phosphate, and Ca2+ and chloride channels (Olmos-Ortiz et al., 2015). 
146 The VDR and regulatory metabolic enzymes are expressed in both placenta and decidua, 
147 indicating a potential critical point in the immunomodulation at the maternal-fetal interface 
148 (Vijayendra Chary et al., 2015b). Further, activities of vitamin D response element (VDRE)-
149 containing genes can be grouped in quite diverse biological networks: bone and mineral 
150 metabolism; cell life and death (comprising proliferation, differentiation and apoptosis); 
151 immune function—both innate and adaptive immunity that are thought to be operational 
152 during the various stages of pregnancy (Knabl et al., 2017).
153 During pregnancy, there are major adaptations in vitamin D metabolism. After conception, 
154 the fertilized egg undergoes a series of reproductive cell divisions to form the three germ 
155 layers—endoderm, mesoderm, and ectoderm) that give rise to different types of cells, many 
156 of which express the vitamin D receptor (VDR) (Kaludjerovic and Vieth, 2010). Various 
157 cells give rise to different organs through organogenesis that extends from 4 to 10 weeks of 
158 gestation with the placental fully formed and functional by 4 weeks of gestation. During this 
159 time of immense activity and growth, localized concentrations of vitamin D in the form of 
160 25(OH)D (which crosses the placenta from the maternal side) and 1,25(OH)2D (which is 
161 synthesized by the fetus as early as 6-10 weeks of gestation) can interact with various 
162 signalling systems to regulate organ development (Kaludjerovic and Vieth, 2010). As 
163 mentioned, it is the placenta that permits the transfer of 25(OH)D from the mother to the 
164 fetus but also the placenta through its production of 1α-hydroxylase that local synthesis of 
165 1,25(OH)2D occurs. 1,25(OH)2D binds to VDR in specialized cells to induce genomic and 
166 nongenomic responses that stimulate organ development. 
167 Focusing on 1,25(OH)2D during pregnancy, 1,25(OH)2D increases more than 2–3 fold in the 
168 first weeks of pregnancy that appears to come mainly from maternal kidney synthesis but 
169 some is placentally-derived (Bikle et al., 1984, Hollis et al., 2011, Tamblyn et al., 2018, Best 
170 et al., 2019). This increase is noted in both animal models and human studies as measured by 
171 RIA and LC-Tandem mass spec (LC-MS) and is accompanied by a rise in VDBP, the main 
172 carrier of all vitamin D moieties with greater avidity for 25(OH)D (Bikle et al., 1984, 
173 Vijayendra Chary et al., 2015a, Hollis et al., 2011)(Hollis and Wagner, 2017a, Novakovic et 
174 al., 2009, Best et al., 2019). Despite this, there is no corresponding rise in 25(OH)D during 
175 pregnancy (Hollis and Wagner, 2017a). 
176 The increase in 1,25(OH)2D early in the first trimester of pregnancy is linked to higher 
177 Cyp27B1 (1--hydroxylase) activity in maternal kidney, placental trophoblasts and decidua 
178 (Bikle et al., 1984, Olmos-Ortiz et al., 2015, Whitehead et al., 1981, Hollis et al., 2011). 
179 Longitudinal human studies also report a progressive increase in both bound and free 
180 1,25(OH)2D concentrations (Best et al., 2019). Previous animal studies in partly and 
181 completely nephrectomized rats report that this rise is mainly attributed to increased maternal 
182 synthesis per se, rather than decreased clearance (Gray et al., 1979). This increase in 
183 1,25(OH)2D occurs at a time during pregnancy before increased fetal calcium requirements 
184 manifest, increasing from ~2 mg/day in the first trimester to 100 mg/day in last trimester that 
185 is continued throughout lactation. Yet, immediately after delivery, maternal calcitriol 
186 concentrations return to pre-pregnancy levels, despite significant calcium requirements 
187 needed during lactation (Carneiro et al., 2010, Ritchie et al., 1998). 1,25(OH)2D  
188 concentrations by 12 weeks of gestation have already increased to a mean of 180 pmol/L, 
189 further increasing to around 300 pmol/L toward the end of pregnancy, compared to 
190 nonpregnant control mean concentration of 91 pmol/L (Papapetrou, 2010, Ardawi et al., 
191 1997, Hollis et al., 2011). Calcitriol circulates at low levels in fetal blood, typically less than 
192 50% of the maternal value (Fleischman et al., 1980, Hollis and Pittard, 1984a, Seki et al., 
193 1994, Hillman et al., 1985). Both animal models and human data suggest that 25(OH)D 
194 readily crosses the placenta, with cord blood concentrations that are around 70-100% of 
195 maternal concentrations (Hollis and Pittard, 1984a, Hollis et al., 2011, Best et al., 2019). 
196 Calcitriol synthesis in the fetus is likely suppressed by the high serum calcium, high 
197 phosphorus, and low PTH concentrations typically observed in cord blood (Kovacs, 2014).
198 It is interesting that the rise in maternal 1,25(OH)2D during pregnancy occurs without any 
199 effect on serum ionized or corrected calcium and appears to result from uncoupling of 
200 1,25(OH)2D from its well-established actions in the non-pregnant state (Hollis et al., 2011). 
201 While VDBP increases concomitantly, it does not increase to the same degree as 1,25(OH)2D  
202 (Hollis et al., 2011). In addition, upregulation of CYP27B1 mRNA in the maternal kidneys, 
203 exerts characteristics of “extrarenal” production from an endocrine standpoint, such as 
204 relative unresponsiveness to stimulation by PTH (except under conditions of extreme vitamin 
205 D deficiency) and lack of feedback inhibition of CYP27B1, and thus, 1-α-hydroxylase by 
206 1,25(OH)2D itself. This increase in 1,25(OH)2D seems to be independent of parathyroid 
207 hormone (PTH), which itself remains within the normal adult range throughout pregnancy 
208 (Wagner and Hollis, 2011, Haddow et al., 2011, Hollis et al., 2011). Other hormones could 
209 also contribute to the bioregulation of 1-α-hydroxylase such as PTH-rP, estradiol, prolactin, 
210 and placental lactogen (Ardawi et al., 1997).
211 As shown in Figure 1 below (from Hollis et al, with permission, (Hollis et al., 2011), this 
212 kinetic reaction saturation graph of 25(OH)D and 1,25(OH)2D shows that 25(OH)D has 
213 direct influence on 1,25(OH)2D concentrations throughout pregnancy, an event which does 
214 not occur during any other time during human life. It is apparent in the figure that as lower 
215 concentrations of 1,25(OH)2D increase, first order kinetics becomes zero order kinetics, with 
216 a plateauing of the graph and an inflection point at 100 nmol/L (40 ng/mL) 25(OH)D—the 
217 level required to optimize 1,25(OH)2D production during pregnancy. (Place Figure 1 near 
218 here)
219 Based on these findings, it is thought by some that this inflection point of 100 nmol/L may be 
220 critical during pregnancy for both maternal and fetal well-being, and that attainment of this 
221 threshold early-on may be key. There are data to suggest that vitamin D status early in 
222 pregnancy sets the stage for vitamin D’s enabling effect on immune function (Mirzakhani et 
223 al., 2016, Weiss and Litonjua, 2017). In their post hoc analysis using multivariable log-
224 binomial regression of maternal 25(OH)D status during pregnancy, McDonnell et al reported 
225 that women attaining maternal 25(OH)D concentrations ≥100 nmol/L compared to ≤50 
226 nmol/L, adjusted for covariates, was associated with a reduction in the risk of preterm birth 
227 by 59% (McDonnell et al., 2017).
228 With more modern scientific technological advancement, vitamin D has been shown to act on 
229 innate and structural cells to promote antimicrobial defense through induction of antimicrobial 
230 peptides (e.g. cathelicidin, beta-defensins) and autophagy (Liu et al., 2006, Chun et al., 2014a). 
231 Bridging both innate and adaptive immunity, vitamin D also acts on myeloid dendritic cells 
232 (DC) to promote a tolerogenic antigen presenting cell (APC) phenotype (Penna et al., 2007). 
233 In their recent review, Hawrylowicz and Santos provide compelling evidence that vitamin D 
234 reduces naïve T cell expansion, and downregulates Th1 and Th17 responses, but has variable 
235 effects on Th2 responses linked to allergic disease (Hawrylowicz and Santos, 2019). These 
236 interactions result in an increased frequency of human Foxp3 and IL-10 Treg in vitro and in 
237 vivo (Penna et al., 2005, Van Der Aar et al., 2011, Nikolic and Roep, 2013, Urry et al., 2012, 
238 Pfeffer and Hawrylowicz, 2018, Hawrylowicz and Santos, 2019, Jeffery et al., 2009). 
239 Similarly, Vasiliou et al., in their human dust mite-allergy mouse model, showed that vitamin 
240 D deficiency in utero led to an increased frequency of Th2 cells and reduced anti-inflammatory 
241 IL-10+ T cells in the lungs (Vasiliou et al., 2014), arguing for an in utero process that continues 
242 after birth. As noted by Hawrylowicz and Santos (Hawrylowicz and Santos, 2019), neonatal 
243 and adult immunity differs, and assumptions of how vitamin D promotes protective immunity 
244 in pregnancy and neonates may be distinct to effects in adults, as they note that in recently 
245 published, independent vitamin D supplementation pregnancy studies that showed such 
246 differences (e.g. no correlation with Foxp3) (Hornsby et al., 2018, Chi et al., 2011, Guven et 
247 al., 2012). Clearly, more research is needed in this area to inform the design of more meaningful 
248 clinical trials.
249
250 Translation of laboratory findings to clinical studies
251 Palacios (2019b) concluded that notwithstanding inconsistent reporting of adverse events, 
252 vitamin D supplementation appears safe. Studies presented by CW also showed a high degree 
253 of safety in both mother and fetus/neonate and later, in the offspring during longitudinal 
254 follow-up studies (Hollis et al., 2011, Wagner et al., 2013b, Wagner et al., 2013a, Al-Garawi 
255 et al., 2016, Chawes et al., 2016, Zhang et al., 2016, Litonjua et al., 2016, Wolsk et al., 
256 2017b, Roth et al., 2018b, Hornsby et al., 2018, Stukes et al., 2016, Kelly et al., 2019, 
257 Litonjua et al., 2020). During pregnancy, there was no evidence of toxicity from high 
258 25(OH)D concentrations or differences in maternal serum calcium, phosphorus, and urinary 
259 calcium/creatinine ratios or adverse pregnancy outcomes among the many women who have 
260 been supplemented with various combinations of vitamin D up to 110 g/day or 1250 
261 g/week during pregnancy.  There are some individuals, however, who could develop 
262 toxicity if not previously diagnosed with idiopathic hypercalcemia of childhood associated 
263 with Williams Syndrome (a rare genetic disorder that results in hypercalcemia with even 
264 modest vitamin D supplementation due to abnormal metabolic processing (Aravena et al., 
265 2002) or from other metabolic genetic defects in vitamin D processing such as CYP24A1 
266 mutations (Macdonald et al., 2020). Some studies show benefit to the pregnant woman and 
267 her developing fetus with improved vitamin D status (Rostami et al., 2018) yet others do not 
268 (Roth et al., 2018b), but none have shown toxicity with higher dosing within certain inclusion 
269 and exclusion entry criteria. Despite the known basic science aspects of vitamin D, clinical 
270 trials often fail to note differences in outcomes of supplementation during pregnancy due to a 
271 number of factors listed in Table 1 (place Table 1 near here).
272 Based on animal and clinical studies looking at the effect of vitamin D status at baseline early 
273 in pregnancy and pregnancy outcomes (Liu et al., 2013, Dawodu et al., 2013, Chan et al., 
274 2015, Mirzakhani et al., 2016, Hewison, 2018), it would appear that the most profound 
275 effects of early supplementation are seen in those with the greatest deficiency states at 
276 baseline (Ganguly et al., 2018, Rostami et al., 2018). In addition, it would appear that the 
277 effects are seen more notably when total circulating 25(OH)D is used as the biomarker of 
278 vitamin D status during pregnancy rather than analysed on an intention-to-treat (ITT) basis. 
279 Higher dose effects are more apparent in those who follow the prescribed supplementation 
280 regimen and when the analysis is on a per protocol basis (Abercrombie et al., 2018). Another 
281 consideration is that in a classic drug study with ITT analysis, the concentration of the drug in 
282 question starts at 0 in both the control and treatment group(s); yet, in nutrient studies such as 
283 vitamin D supplementation trials, no one starts at a concentration of zero. For this reason, 
284 Heaney outlined the criteria that should be met for all nutrient studies to avoid this faulty 
285 design (Heaney, 2014). The other question that continues to plague vitamin D studies is what 
286 is really representative of that nutrient—in this case, vitamin D? Is it the parent compound or 
287 a metabolite—25(OH)D, and is that metabolite really indicative of what is going on at the 
288 cellular level? Should the metabolite be measured in its bound form or its free state 
289 (Tsuprykov et al., 2019, Best et al., 2019)?
290 Best et al provide a longitudinal examination of the changes in various moieties of vitamin D 
291 during adolescent pregnancy and included in their analyses free circulating 25(OH)D 
292 measurement as well as VDBP (Best et al., 2019). In their analysis of 58 adolescent pregnant 
293 females, the authors found that regardless of race or visit, total 25(OH)D was a stronger 
294 correlate of PTH, 1,25(OH)2D, and of the catabolite 24,25(OH)2D than free circulating 
295 25(OH)D, and neither total nor free 25(OH)D was related to serum calcium. While African 
296 American pregnant girls had lower total 25(OH)D (p < 0.0001), their free 25(OH)D did not 
297 significantly differ by race (p = 0.2). Of interest, in these pregnant adolescents, VDBP 
298 concentration was elevated and inversely associated with the percent free 25(OH)D, but 
299 measured free 25(OH)D provided no advantage over total 25(OH)D as a predictor of PTH, 
300 1,25(OH)2D, 24,25(OH)2D, or calcium. Thus, it appears for the moment that total circulating 
301 25(OH)D concentration is the best indicator of vitamin D status. 
302 Other issues in assessing vitamin D status during pregnancy and its relevance to outcomes 
303 includes the question of whether baseline 25(OH)D in a study represents the 25(OH)D 
304 concentration circulating around the time of conception. Vitamin D supplementation as a 
305 treatment is plagued with nonadherence whereas using 25(OH)D as the biomarker is not. 
306 There are also issues of whether or not total circulating 25(OH)D is reflective of vitamin D 
307 metabolism within the cell, especially with variable bolus dosing. Perhaps it is baseline 
308 25(OH)D in early pregnancy or even preconception that is more relevant in showing the 
309 effect of vitamin D status on the fetal and maternal health, but to date, no trials have 
310 addressed circulating 25(OH)D at the time of conception and placental activity. 
311 Systematic reviews and meta-analyses of vitamin D supplementation during pregnancy show 
312 mixed results in prevention of preeclampsia and preterm birth, which may reflect timing of 
313 supplementation initiation as well as study design in terms of dosing regimen and maternal 
314 vitamin D status starting point (as noted in Table 1). The differences between in vitro and 
315 animal studies results of vitamin D’s role as an enabler and the often-null results of 
316 randomized controlled trials challenges us to explore alternative hypotheses and to design 
317 studies that integrate these divergent findings.   
318 Another factor that could potentially affect study results includes estimation of sample size. 
319 On what do we base the sample size of a clinical trial? Is it anticipated treatment effects such 
320 as preeclampsia, hypertension, gestational diabetes, or changes in a particular relevant 
321 biomarker such as T cell phenotype? Another question is when in pregnancy do you look for 
322 effect? What biomarker is most appropriate? Should sample size be based on VDBP 
323 genotype, specific SNPs or ethnicity, all of which affect vitamin D metabolism? These 
324 questions impact study design but also data analysis. Such questions influence clinical study 
325 design and create limitations in our ability to interpret the data in a meaningful manner. As 
326 has been the case with the advent of scientific inquiry, the basis for what we prescribe 
327 clinically must have a demonstrated rationale that befits the data and the laboratory, and 
328 which can be translated to bedside practices with continued meaning and relevance. Without 
329 study design that incorporates the nature of the system—in this case a hormonal system that 
330 has many functions—we will fail to see benefit and make conclusions that might be 
331 premature or biased. Through careful understanding of cellular mechanisms that may be 
332 influencing its demonstrated effect and a broader systems-based approach across mother, 
333 placenta and fetus, we will move closer to a greater understanding of the dynamic effect of 
334 vitamin D during pregnancy on both the mother and her developing fetus.
335 Alternative perspective based on evidence from published RCTs of prenatal vitamin D 
336 supplementation
337 While acknowledging the well-justified enthusiasm for the potential benefits of improving 
338 vitamin D status in the prenatal period, Dan Roth (DR) presented a summary of selected 
339 high-quality RCTs showing  insufficiently convincing evidence to merit widespread changes 
340 to clinical practice guidelines or policy (Roth et al., 2018a). As of the end of 2019, the World 
341 Health Organization (WHO) advises that, “vitamin D supplementation is not recommended 
342 for pregnant women to improve maternal and perinatal outcomes” (World Health 
343 Organization, 2016). While there is little doubt that prenatal vitamin D supplementation 
344 improves maternal and fetal vitamin D status in a dose-dependent manner, the clinical 
345 benefits to the mother and baby remain a subject of debate (Palacios et al., 2019b, Roth et al., 
346 2017, Palacios et al., 2019a).  The question is whether additional vitamin D during 
347 pregnancy, over and above that required by a non-pregnant woman, is required. To illustrate 
348 how prenatal vitamin D RCTs have so far failed to provide robust evidence of clinical 
349 benefits, it is instructive to consider five published blinded RCTs that each included at least 
350 500 enrolled women, were generally of high-quality, and for which publication in reputable 
351 journals suggests they underwent thorough peer review (Table 2) Place Table 2 near here. 
352 None of these five trials individually demonstrated a beneficial effect of the vitamin D 
353 intervention on their primary outcomes, as reported in the original trial publications (Table 
354 3). For other secondary outcomes of interest (e.g., birth weight, gestational age at birth or 
355 preterm, neonatal or infant hospitalization, or gestational hypertension or preeclampsia), none 
356 of these trials provided strong evidence of benefits of vitamin D (i.e., either the outcome was 
357 reported and the effect was null or non-significant, or the outcome was not reported) (Roth et 
358 al., 2018b, Litonjua et al., 2016, Cooper et al., 2016, Chawes et al., 2016, Hollis et al., 2011). 
359 Importantly, these trials reported adverse event monitoring and none have raised major safety 
360 concerns, so the overall inference is that prenatal vitamin D supplementation safely raises 
361 25(OH)D without clearly providing other benefits to pregnant women and babies. 
362 However, further efforts to unpack the results of some of these trials have led to alternative 
363 interpretations based on sub-group effects, post-hoc secondary analyses, and longer-term 
364 follow-up studies. For example, in their original trial report, Hollis et al. (2011) did not find 
365 any significant differences in maternal and neonatal clinical outcomes (Hollis et al., 2011); 
366 however, in a post-hoc analysis adjusting for race, published in 2013, Hollis and Wagner 
367 wrote that, “the data from our RCT strongly suggest that vitamin D supplementation during 
368 pregnancy can significantly decrease complications of pregnancy including primary 
369 caesarean section (p=0.046), hypertensive disorders of pregnancy (p=0.05) and comorbidities 
370 of pregnancy (p=0.03)” (Hollis and Wagner, 2013). This particular interpretation of the trial 
371 continues to be cited as direct evidence of the clinical benefits of high-dose prenatal vitamin 
372 D supplementation (Hollis, 2019). In the primary report of the MAVIDOS trial, a planned 
373 sub-group analysis indicated that vitamin D supplementation increased bone mineral content 
374 in newborns delivered in the winter, in contrast to the overall null findings of the trial 
375 (Cooper et al., 2016). Yet, conference presentations, press releases and news stories about 
376 MAVIDOS frequently highlighted this sub-group effect and emphasized the potential 
377 benefits of vitamin D (Grey and Bolland, 2016). Two of the five major trials (VDAART and 
378 COPSAC) had similar primary outcomes related to early-childhood wheeze and asthma, and 
379 the pooled analysis of these trials indicated that vitamin D significantly reduced the incidence 
380 of asthma or recurrent wheeze in the offspring up to three years of age (Wolsk et al., 2017a). 
381 However, follow-up of the children in one of the trials showed no sustained effects, such that 
382 the prevalence of asthma diagnoses by age 6 years was similar between the vitamin D and 
383 control groups (Brustad et al., 2019). 
384 Researchers and practitioners who conduct and interpret vitamin D RCTs are faced with a 
385 dilemma when the primary results of a trial conflict with – or are less convincing than – other 
386 post-hoc or alternative analyses of the same data, especially if the latter analyses support their 
387 original hypothesis. Retaining the original randomized design, including all participants in 
388 the analyses, and applying an intent-to-treat approach are all strategies that serve to reduce 
389 biases, but there is often an appeal to dissect the data in other ways that are believed to reveal 
390 hidden truths about physiology that may be obscured by the bluntness of the RCT approach 
391 (Figure 2). Conventional analysis of a RCT is by no means a sure-fire path to clarity, and no 
392 trial is without its limitations. For example, the placebo-controlled dose-ranging RCT of 
393 prenatal vitamin D in Bangladesh from Roth and colleagues was specifically designed to test 
394 whether vitamin D improves infant growth in a setting where stunting is common (Roth et al., 
395 2018b). It was not designed or powered to examine effects on uncommon maternal or 
396 perinatal outcomes, and it is possible that the initiation of supplementation in the 2nd trimester 
397 was too late to affect some outcomes such as preeclampsia (Roth et al., 2018b). Other aspects 
398 of the trial may have limited its generalizability to the broader population of Bangladeshi 
399 women (e.g., perhaps trial participants were healthier than average) or to populations outside 
400 of Bangladesh (e.g., perhaps the trial participants’ concurrent nutritional deficiencies 
401 constrained the effects of vitamin D). Place Figure 2 near here
402 Unfortunately, systematic reviews and meta-analyses of RCTs can further confuse rather than 
403 clarify the state of the evidence, as their conclusions can only be as robust as the underlying 
404 evidence on which they are based (Roth et al., 2017). For example, authors of the recent 
405 update of the Cochrane Collaboration systematic review of vitamin D in pregnancy had to 
406 rely on mostly small trials of low or questionable quality to draw conclusions about the 
407 effects of vitamin D (versus placebo) on maternal and neonatal outcomes (Palacios et al., 
408 2019a). In summarizing one of the meta-analyses, Palacios et al. wrote that, 
409 “supplementation with vitamin D probably reduces the risk of pre-eclampsia compared to no 
410 intervention or placebo (risk ratio (RR 0.48, 95% CI 0.30 to 0.79)” and they considered this 
411 to be based on “moderate-certainty evidence” (Palacios et al., 2019a). This conclusion is 
412 reiterated prominently in the abstract and plain-language summary, and if true, would be of 
413 considerable public health importance. However, scrutiny of the four trials on which this 
414 finding was based reveals the weakness of the conclusion. The aggregated sample size was 
415 only 499 women (Palacios et al., 2019a), far lower than what would be required in a primary 
416 prevention trial designed for precise estimation of effects of a prenatal intervention on 
417 preeclampsia. Only one of the four trials reported having any type of prospective 
418 ascertainment protocol and standardized case definition for preeclampsia (Behjat Sasan et al., 
419 2017), and all of the published trial reports lack sufficient information to confidently establish 
420 the reliability of their findings (Asemi et al., 2013, Sablok et al., 2015, Behjat Sasan et al., 
421 2017, Naghshineh and Sheikhaliyan, 2016). Furthermore, reviews that incorporated other 
422 trials (including those in which control groups received a low-dose of vitamin D) do not 
423 support a beneficial effect of additional vitamin D for prevention of preeclampsia, at least not 
424 beyond the amount in conventional prenatal multiple micronutrient supplements (5-15 
425 g/day) (Palacios et al., 2019b, Roth et al., 2017). 
426 To date, there have not been any rigorous and adequately powered RCTs of prenatal vitamin 
427 D supplementation for the prevention of hypertensive diseases of pregnancy or other adverse 
428 maternal outcomes (Palacios et al., 2019b, Roth et al., 2017, Palacios et al., 2019a). Authors 
429 of reviews or commentaries may conclude that vitamin D prevents pregnancy complications 
430 if their meta-analysis was methodologically flawed (e.g., biased study selection, errors in data 
431 abstraction) (Fogacci et al., 2019) or focused entirely on observational studies that cannot 
432 provide evidence of causal effects (Tous et al., 2019, Zhou et al., 2017, Yuan et al., 2019). In 
433 a recent article, Hollis recently wrote that, “Most of these clinical trials have validated the 
434 positive effects of prenatal vitamin D on birth outcomes …,” (Hollis, 2019) citing four 
435 published articles to support his claim: 1) an Iranian study that reported a lower frequency of 
436 preeclampsia, preterm delivery and adverse pregnancy outcomes at a hospital that conducted 
437 screening for vitamin D deficiency and provided supplementation, compared to a control 
438 hospital in another city (Rostami et al., 2018) (limitations of this study were highlighted in a 
439 letter to the editor (Shub and McCarthy, 2019)); 2) a secondary analysis of VDAART that 
440 examined asthma/wheeze outcomes but did not report on any birth outcomes (Wolsk et al., 
441 2017b); 3) another secondary analysis of VDAART that found there was no effect of vitamin 
442 D supplementation on preeclampsia risk based on the RCT design, but did find an association 
443 between 25(OH)D and preeclampsia using a cohort analysis (Mirzakhani et al., 2016); and, 4) 
444 an observational study of the association between 25(OH)D and preterm birth (McDonnell et 
445 al., 2017). There are certainly many studies suggesting that prenatal vitamin D 
446 supplementation may have benefits, including some small RCTs; however, an unbiased 
447 assessment must take stock of the entire body of evidence, taking into account study design 
448 and quality.  
449 A pragmatic approach - setting the maternal vitamin D requirement to safeguard the fetal 
450 skeleton by targeting threshold 25-hydroxyvitamin D concentrations
451 MK proposed the possibility that given the various determinants of perinatal outcomes, 
452 including personal, genetic and healthcare factors, as well as overall diet and nutrition, it may 
453 be a too tall order to expect a single nutrient intervention to deliver dramatically improved 
454 outcomes. This may be true both in low resource settings, where malnutrition is common, or 
455 where there are no maternal or neonatal supplementation policies, but also in countries with 
456 well-nourished, healthy mothers who have 25(OH)D status at baseline in excess of 50 nmol/L 
457 and excellent obstetric care. Irrespective of the potential benefits of additional 25(OH)D to 
458 enable the establishment and maintenance of a healthy pregnancy, the complete dependence 
459 of the fetus and newborn infant on maternal 25(OH)D concentrations has been consistently 
460 reported (Hollis and Pittard, 1984b). It is widely accepted that at minimum, very low 
461 25(OH)D (<25-30 nmol/L) during pregnancy should be prevented to protect fetal skeletal 
462 development (Munns et al., 2016). As cord 25(OH)D concentration is usually lower than the 
463 corresponding maternal concentration (Hollis and Pittard, 1984b) and others, prevention of 
464 maternal 25(OH)D below 25-30 nmol/L may not provide fetal and neonatal protection (Kiely 
465 et al., 2016). Current recommendations for vitamin D during pregnancy do not consider the 
466 vitamin D requirement of newborn infants and assume the immediate availability of an 
467 adequate supply from early life. Therefore, Kiely et al (2017a) proposed prevention of 
468 neonatal vitamin D status <25-30 nmol/L, indicated by umbilical cord 25(OH)D, as a 
469 potential target for defining maternal vitamin D requirements during pregnancy, consistent 
470 with prevention of nutritional rickets (Munns et al., 2016). In a placebo-controlled dose-
471 response RCT, O’Callaghan et al (2018) reported that maintaining maternal 25(OH)D 
472 concentrations > 50 nmol/L at the end of pregnancy ensured that cord sera were all > 25 
473 nmol/L. The vitamin D3 intake required to maintain maternal 25(OH)D > 50 nmol/L in 
474 almost all mothers was 30 g/day (1200 IU) (O'Callaghan et al., 2018), which is twice the 
475 current US and EU recommendation of 600 IU. This study confirmed suggestions from two 
476 RCTs in Canada (March et al., 2015) and New Zealand (Grant et al., 2014), that although 10 
477 μg vitamin D per day may prevent maternal 25(OH)D falling below 30 nmol/L, a minimum 
478 of 25 μg/d might be needed to maintain newborn 25(OH)D at this concentration. Further 
479 similar dose-response studies are required in different racial and ethnic groups and in various 
480 settings to generate an inclusive estimate of maternal vitamin D requirements for the 
481 prevention of neonatal deficiency. Adequate consideration of calcium intake is required in 
482 these studies. Calcium is infrequently considered in RCTs of vitamin D and perinatal health 
483 although its role in the calcium metabolic system and maintenance of normal PTH 
484 concentrations is linked to perinatal health (Hofmeyr et al., 2014, Hemmingway et al., 2018). 
485 Conclusions
486 Laboratory science is driving our understanding of the role of vitamin D in healthy 
487 pregnancy, most recently from the perspective of immune function. At a fundamental level, 
488 the role of vitamin D in skeletal development has been accepted for many years, but the 
489 particular needs of pregnant women and newborn infants, a high risk sector of the population, 
490 have been underserved. While clinical practice guidelines are potentially more responsive to 
491 new evidence, public health nutrition recommendations are infrequently updated, creating a 
492 lengthy gap between the clinical research evidence base and its translation into guidance. 
493 National/international policy implementation is often slow or non-existent, contributing to a 
494 wide dichotomy between the state of the art and public policy, manifested in gross 
495 inequalities in health care provision and poor outcomes for at risk mothers and babies. This is 
496 evidenced by the wide variation in vitamin D status and rates of nutritional rickets among at-
497 risk groups within and between countries. 
498 In the face of such uncertainty, where do we go from here? Even without strong evidence 
499 from RCTs, it would be reasonable and safe for public health authorities to take a population 
500 approach that aims to eliminate the prevalence of 25(OH)D <30 nmol/L and facilitate 
501 achievement of a personal target of 50 nmol/L, including among women of reproductive age 
502 (Kiely et al., 2017a; Roth et al., 2018a). In this scenario, fortification of staple foods with 
503 vitamin D (Roth et al., 2018a) and scale-up of use of antenatal multiple micronutrient 
504 supplements (Sudfeld and Smith, 2019) (which include modest amounts of vitamin D) will 
505 likely achieve this aim and reduce the risk of severe vitamin D deficiency. 
506 To determine if higher intakes of vitamin D are required in pregnancy, the optimal strategy 
507 would be to conduct a large-scale RCT of prenatal vitamin D supplementation that goes 
508 beyond the scope of any previous or ongoing RCT: multi-country collaboration (including 
509 both high- and lower-income settings), early first trimester (or preconception) enrolment, 
510 factorial design with calcium, and designed and powered for uncommon maternal outcomes 
511 (preeclampsia, intrauterine death), preterm birth, and longer-term child health outcomes 
512 (including nutritional rickets). Such a trial would be financially costly and logistically 
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965
966 Table 1. Factors Affecting Clinical Outcomes of Vitamin D Supplementation Trials 
967 during Pregnancy
968
 Timing of intervention: when in gestation did 
supplementation occur
 Sample size
 Baseline serum 25(OH)D: e.g., the most profound effects 
of early supplementation seen in those with the lowest 
25(OH)D concentrations at baseline
 Sunshine exposure
 Habitual vitamin D and calcium intake
 Race/ethnicity 
 VDBP genotype
 Dosing frequency of vitamin D: daily vs. weekly vs. 
monthly dosing
 Adherence to dosing regimen
 Types of assays used to measure 25(OH)D concentration
 Type of analysis—Intention-to-treat vs. per protocol
 Biomarker used for vitamin D status: Is total circulating 
25(OH)D concentration really the biomarker of what is 
going on at the cellular level during pregnancy? Should 






973 Table 2. Characteristics and primary findings of five randomized controlled trials of 
974 prenatal vitamin D supplementation* 
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976 *Trials selected if they were double-blind and enrolled >500 participants.
977
978
979 Relationship of 25(OH)D and 1,25(OH)2D during Pregnancy
980
981 Figure 1.  Substrate-Product Relationships of Vitamin D Metabolites during Pregnancy.  
982 This panel demonstrates the relationship circulating 25(OH)D to control the production of 
983 1,25(OH)2D during pregnancy. All data points for all subjects in all groups were included in 
984 this analysis.





























992 Figure 2. Schematic representation of the advantages and disadvantages of approaches 
993 available to investigators when analyzing data from a randomized controlled trial. The 
994 horizontal axis reflects the spectrum of choices related to the participant selection criteria. For 
995 example, a discrete sub-group analysis may involve restriction to participants with baseline 
996 25(OH)D<30 nmol/L, whereas population-representative sampling would include all 
997 participants irrespective of baseline characteristics, adherence, or other non-random factors. 
998 The vertical axis reflects the spectrum of choices related to the assignment of the exposure 
999 variable. An intention-to-treat approach entails direct comparisons of the experimental versus 
1000 control groups, relying only on the random assignment regardless of adherence or 
1001 completeness of follow-up; in contrast, observational analyses usually ignore the random 
1002 allocation and instead examine the association between an outcome and a non-random 
1003 indicator of vitamin D status (e.g., 25(OH)D or number of vitamin D doses received). 
1004
1005
